Photocure Announces Cevira’s Successful Phase III Results

Photocure ASA (PHCUF) has released an update.

Photocure ASA has announced that its partner, Asieris Pharmaceuticals, will present Phase III clinical trial data for the non-surgical cervical HSIL treatment, Cevira (APL-1702), at a conference in Germany. The trial met its primary efficacy endpoint and showed a higher regression rate in the treatment group compared to placebo. Cevira is a photodynamic drug-device combination product that has shown promise in treating high-grade squamous intraepithelial lesions without surgery.

For further insights into PHCUF stock, check out TipRanks’ Stock Analysis page.